Pharmaceutical News

RSS

Former ESC president judged guilty of severe misconduct over drug ties

A British cardiologist and former president of the European Society of Cardiology (ESC) has been judged by the ESC to have committed severe misconduct after a Danish TV documentary reported that he had been involved in drawing up guidelines for the use of the heart drug ivabradine (Corlanor, Procoralan) while profiting from lucrative contracts with the drug's maker.

27 Aug 2026

FDA approves first RAS-targeted therapy for metastatic pancreatic cancer

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

27 Aug 2026

Metformin cuts preterm birth risk among high-risk mothers

A common diabetes medication can reduce the risk of early and preterm births for mothers at high metabolic risk, according to new research led by Monash University.

26 Aug 2026

GLP-1 drugs may reshape obesity care, but clinicians still have questions

Interviews with 11 healthcare professionals in a UK specialist weight management service found generally positive attitudes toward injectable GLP-1 drugs, alongside limited formal training and uncertainty about how the medications should be integrated with behavioral care. Participants anticipated potential benefits for confidence and weight management but also raised concerns about treatment discontinuation, behavioral engagement, and evolving professional responsibilities.

26 Aug 2026

Nigerian COVID-19 response highlights cultural trust in ethnopharmacology

During COVID-19, ethnopharmacology became prominent in Nigeria due to affordability, accessibility, and cultural trust, but evidence for safety and efficacy remains limited.

25 Aug 2026

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with a lower risk of tuberculosis in people with type 2 diabetes compared with sulfonylureas, metformin, DPP-4 inhibitors, and SGLT2 inhibitors. The observational findings suggest a possible benefit beyond metabolic control, but the authors emphasize that prospective and mechanistic studies are needed to determine whether GLP-1 therapies themselves reduce TB risk.

24 Aug 2026

Japan vaccinated heavily during COVID-19. Why are so many unsure about vaccinating next time?

A nationwide Japanese survey found that only 53.1% of respondents said they would accept vaccination in a hypothetical future pandemic with COVID-19-like fatality, despite substantially higher previous COVID-19 vaccine uptake. Willingness varied by demographics, perceived disease risk, exposure to misinformation, vaccine characteristics, and practical factors such as cost, evidence, professional recommendations, and accessibility.

24 Aug 2026

Semaglutide’s heart benefits may partly involve reduced inflammation

A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.

24 Aug 2026

Potassium-competitive acid blockers match proton pump inhibitors for preventing bleeding after PCI

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) increases the risk of upper gastrointestinal bleeding (UGIB).

20 Aug 2026

Why pregnancy vaccination looks very different in Germany than it did 19 years ago

A 19-year German claims analysis of more than 2.8 million pregnancies found that recorded maternal vaccination increased substantially after national recommendations for influenza and pertussis immunization were introduced. Influenza vaccination reached 19.4% and pertussis vaccination about 37% in 2020-2022, while COVID-19 vaccination was not captured in the databas

19 Aug 2026

Most Americans still believe outdated antibiotic guidance, study finds

"Always finish your antibiotics" is no longer considered medical best practice for all conditions.

13 Aug 2026

SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced the introduction of CHO.SET® 2.0. The expanded library of novel and patentable synthetic promoters is designed to improve protein production in CHO (Chinese Hamster Ovary) cells.

From SynGenSys Ltd. 13 Aug 2026

Pediatric leucovorin use spiked after federal officials touted its benefits for autism

Leucovorin prescriptions for children spiked after federal officials claimed the drug was an effective treatment for autism during a September 2025 press conference, according to a new Michigan Medicine-led study published in The New England Journal of Medicine.

12 Aug 2026

Researchers find unexpected protein regulator of leukemia drug sensitivity

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

12 Aug 2026

Insilico Medicine nominates powerful oral drug candidate for the management of heart risks

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the nomination of ISM0900, a potent, AI-driven, highly selective, orally available small molecule inhibitor of lipoprotein(a), or Lp(a), as a preclinical candidate (PCC) for the management of cardiovascular risks.

12 Aug 2026

Modern blood thinners slow cognitive decline in Alzheimer's patients

People with both atrial fibrillation and Alzheimer's disease who are treated with modern NOAC blood-thinning medicines may experience a slower rate of cognitive decline.

12 Aug 2026

Dexamethasone calms lung inflammation without weakening core immune responses

Researchers from Trinity College Dublin and St. James's Hospital have shown that dexamethasone, a commonly prescribed anti-inflammatory steroid, can reduce harmful inflammation triggered by Mycobacterium avium without weakening the ability of human immune cells to control the infection.

11 Aug 2026

New study identifies key pathway for delivering antisense cancer drugs

Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer.

11 Aug 2026

Semaglutide slows blood protein signature linked to future dementia risk

A post hoc analysis of 2,970 older SELECT participants found that semaglutide slowed worsening of a 25-protein blood signature that predicts future dementia risk. Over 104 weeks, semaglutide produced larger effects on modeled 5-year than 20-year dementia risk, but whether these biomarker changes translate into less cognitive decline or dementia remains unknown.

10 Aug 2026

Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes

In a US cohort of 52,971 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide initiation was associated with a lower one-year risk of major adverse cardiovascular events than sitagliptin. The benefit was driven mainly by lower myocardial infarction and all-cause mortality hazards, although the authors cautioned that mortality findings may be influenced by residual confounding.

10 Aug 2026

Pharmaceutical News

Former ESC president judged guilty of severe misconduct over drug ties

FDA approves first RAS-targeted therapy for metastatic pancreatic cancer

Metformin cuts preterm birth risk among high-risk mothers

GLP-1 drugs may reshape obesity care, but clinicians still have questions

Nigerian COVID-19 response highlights cultural trust in ethnopharmacology

Researchers link GLP-1 drugs to lower tuberculosis risk in type 2 diabetes

Japan vaccinated heavily during COVID-19. Why are so many unsure about vaccinating next time?

Semaglutide’s heart benefits may partly involve reduced inflammation

Potassium-competitive acid blockers match proton pump inhibitors for preventing bleeding after PCI

Why pregnancy vaccination looks very different in Germany than it did 19 years ago

Most Americans still believe outdated antibiotic guidance, study finds

SynGenSys introduces expanded CHO.SET synthetic promoter library for enhanced biomanufacturing

Pediatric leucovorin use spiked after federal officials touted its benefits for autism

Researchers find unexpected protein regulator of leukemia drug sensitivity

Insilico Medicine nominates powerful oral drug candidate for the management of heart risks

Modern blood thinners slow cognitive decline in Alzheimer's patients

Dexamethasone calms lung inflammation without weakening core immune responses

New study identifies key pathway for delivering antisense cancer drugs

Semaglutide slows blood protein signature linked to future dementia risk

Tirzepatide lowers heart attack and cardiovascular event risk in adults with type 2 diabetes

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News